Document:

BOARD OF DIRECTORS AGREEMENT

 

This Board of Directors Agreement (“Agreement”)
made as of October 17, 2012 by and between Apollo Medical Holdings, Inc., with its principal place of business at 700 N. Brand
Blvd, Suite 450, Glendale, California, 91203 (“ApolloMed”) and Mark A. Meyers, with an address of 19202 Cerro Villa
Dr, Villa Park, CA, 92861, (the “Director”) provides for director services, according to the following terms and
conditions:

 

I.      Services Provided

 

ApolloMed agrees to engage the Director to serve on the Board
of Directors of ApolloMed and to provide those services required of a director under ApolloMed’s Certificate of Incorporation
and Bylaws, as both may be amended from time, to time (“Articles and Bylaws”) and under the General Corporation Law
of Delaware, the federal securities laws and other state and federal laws and regulations, as applicable.

 

II.      Nature of Relationship

 

The Director is an independent contractor and will not be deemed
an employee of ApolloMed for purposes of employee benefits, income tax withholding, F.I.C.A. taxes, unemployment benefits or otherwise. 
The Director shall not enter into any agreement or incur any obligations on ApolloMed’s behalf.

 

ApolloMed will supply, at no cost to the Director:  periodic
briefings on the business, director packages for each board and committee meeting, copies of minutes of meetings and any other
materials that are required under ApolloMed’s Articles and Bylaws or the charter of any committee of the board on which the
Director serves and any other materials which may, by mutual agreement, be necessary for performing the services requested under
this Agreement.

 

III.      Director’s Warranties

 

The Director warrants that no other party has exclusive rights
to his services in the specific areas in which ApolloMed is conducting business and that the Director is in no way compromising
any rights or trust between any other party and the Director or creating a conflict of interest as a result of his participation
on the Board of Directors of ApolloMed.  The Director also warrants that so long as the Director serves on the board of the
directors of ApolloMed, the Director will not enter into another agreement that will create a conflict of interest with this Agreement. 
The Director further warrants that he will comply with all applicable state and federal laws and regulations, as applicable, including
Sections 10 and 16 of the Securities and Exchange Act of 1934.

 

Throughout the term of this Agreement, the Director agrees he
will not, without obtaining ApolloMed’s prior written consent, directly or indirectly engage or prepare to engage in any
activity in competition with any ApolloMed business or product, including products in the development stage, accept employment
or provide services to (including service as a member of a board of directors), or establish a business in competition with ApolloMed.

 

IV.      Compensation

 

A.  Cash Fee

 

During the term of this Agreement, ApolloMed shall pay the Director
a nonrefundable fee of $1,000 per board of director meeting in consideration for the Director providing the services described
in Section I which shall compensate him for all time spent preparing for, travelling to (if applicable) and attending board of
director meetings; provided, however, that if any board meetings or duties require out-of-town travel time, such additional travel
time may be billed at the rate set forth in subparagraph C of Section IV below.  This cash fee may be revised by action of
ApolloMed’s Board of Directors from time to time.  Such revision shall be effective as of the date specified in the
resolution for payments not yet earned and need not be documented by an amendment to this Agreement.

 

    	1

    	 

    

 

B.    Equity Compensation

 

Issuance of Shares. Upon the execution and delivery of
this Agreement, ApolloMed shall issue to the Director (or designee of the Director) a restricted stock award of 400,000 shares
of ApolloMed’s common stock (collectively, the “Shares”). Pursuant to the request of the Director, all of the
Shares shall be issued in the name of “___Mark A. Meyers_________” and the Shares that have not been released
from Escrow (as defined herein below) may not be sold, pledged, hypothecated or otherwise transferred to any other person. All
certificates representing the Shares shall bear a legend regarding the fact that the Shares are not registered under the Securities
Act of 1933, as amended (the “Securities Act”), and none of the Shares may be sold, pledged, hypothecated or otherwise
transferred without compliance with Federal and applicable state securities laws.

 

Escrow of Shares. Certificates evidencing all Shares
shall be placed in escrow maintained at all times by the Company (“Escrow”). Provided this Agreement has not been previously
terminated, on the last day of each month during the term of this Agreement, 1/36th of the total number of Shares
shall be promptly released from Escrow by ApolloMed to the Director. If the Agreement is terminated prior to the end of any
calendar month during the term of this Agreement, for any reason or for no reason, and regardless of the party who initiated the
termination, the Director shall receive a pro-rata number of Shares for that calendar month based upon the actual number of days
elapsed prior to the date of termination. Except as set forth in the immediately preceding sentence, upon the termination of this
Agreement, for any reason or for no reason, and regardless of the party who initiated the termination, no additional Shares shall
be released from Escrow. Unless otherwise agreed to by ApolloMed and the Director in writing, if this Agreement remains in effect
for more than 36 months, no additional shares shall be issued to the Director hereunder. Notwithstanding anything contained herein
to the contrary, the Shares shall be issued and released from Escrow only in full compliance with Federal and all applicable state
securities laws and the Director shall cooperate with all requests of ApolloMed in order to comply with all such laws as may be
reasonably requested by the Company or its counsel. The Shares do not carry registration rights and the Director has no right to
compel the registration of any of the Shares, either before or after they are released from Escrow. Additionally, the Director
covenants and agrees to be bound by all standard policies and guidelines applicable to the other directors and executive officers
of ApolloMed with respect to transaction in the Shares, including without limitation the terms and conditions of any insider trading
policy, code of ethics, corporate governance guidelines, or similar policies, codes and guidelines adopted by the Board of Directors
of ApolloMed from time to time. 

 

Repurchase Obligation. Upon the termination of this Agreement,
for any reason or for no reason, and regardless of the party who initiated the termination, any Shares which ApolloMed is not yet
obligated to released from Escrow (“Repurchased Shares”) shall be repurchased by the Company at a price of $0.0001
per Repurchased Share (the “Repurchase Per Share Price”). ApolloMed shall remit its check to the Director within 10
business days following such termination in the full amount of the Repurchase Per Share Price multiplied by the number of Repurchased
Shares. For example, if there were 100,000 Shares remaining in Escrow upon the termination of this Agreement, ApolloMed would repurchase
the 100,000 Shares by remitting its check to the Director in the amount of 100,000 x $0.0001 = $10.00.

 

C.    Additional Payments

 

To the extent services described in Section I require out-of-town
trips, such additional travel time may be charged at the rate of $1,200 per day or pro rated portion thereof.   This
rate may be revised by action of ApolloMed’s Board of Directors from time to time for payments not yet earned.  Such
revision shall be effective as of the date specified in the resolution and need not be documented by an amendment to this Agreement.

 

    	2

    	 

    

 

D.    Payment

 

Cash fees shall be made quarterly in cash in advance on the
first day of each accounting quarter.  Additional payments shall be made in arrears.  No invoices need be submitted by
the Director for payment of the cash fee.  Invoices for additional payments under subparagraph C of Section IV, above, shall
be submitted by the Director. Such invoices must be approved by ApolloMed’s Chief Executive Officer as to form and completeness.

 

E.    Expenses

 

ApolloMed will reimburse the Director for reasonable expenses
approved in advance, such approval not to be unreasonably withheld.  Invoices for expenses, with receipts attached, shall
be submitted. Such invoices must be approved by ApolloMed’s Chief Executive Officer as to form and completeness.

 

V.      Indemnification and Insurance

 

ApolloMed will execute an indemnification agreement in favor
of the Director substantially in the form of the agreement attached hereto as Exhibit B (the “Indemnification Agreement”). 
In addition, so long as ApolloMed’s indemnification obligations exist under the Indemnification Agreement, ApolloMed shall
provide the Director with directors and officers liability insurance coverage in the amounts specified in the Indemnification Agreement.

 

VI.      Term of Agreement

 

This Agreement shall be in effect from the date hereof through
the last date of the Director’s current term as a member of ApolloMed’s Board of Directors.  This Agreement shall
be automatically renewed on the date of the Director’s reelection as a member of ApolloMed’s Board of Director’s
for the period of such new term unless the Board of Directors determines not to renew this Agreement.   Any amendment
to this Agreement must be approved by a written action of ApolloMed’s Board of Directors.  Amendments to Section IV
Compensation hereof do not require the Director’s consent to be effective.

 

VII.      Termination

 

This Agreement shall automatically terminate upon the death
of the Director or upon his resignation or removal from, or failure to win election or reelection to, the ApolloMed Board of Directors.

 

In the event of any termination of this Agreement, the Director
agrees to return or destroy any materials transferred to the Director under this Agreement except as may be necessary to fulfill
any outstanding obligations hereunder.  The Director agrees that ApolloMed has the right of injunctive relief to enforce this
provision.

 

ApolloMed’s and the Director’s continuing obligations
hereunder in the event of such termination shall be subject to the terms of Section XIV hereof.

 

VIII.      Limitation of Liability

 

Under no circumstances shall ApolloMed be liable to the Director
for any consequential damages claimed by any other party as a result of representations made by the Director with respect to ApolloMed
which are materially different from any to those made in writing by ApolloMed.

 

Furthermore, except for the maintenance of confidentiality,
neither party shall be liable to the other for delay in any performance, or for failure to render any performance under this Agreement
when such delay or failure is caused by Government regulations (whether or not valid), fire, strike, differences with workmen,
illness of employees, flood, accident, or any other cause or causes beyond reasonable control of such delinquent party.

 

    	3

    	 

    

 

IX.      Confidentiality

 

The Director agrees to sign and abide by ApolloMed’s Director
Proprietary Information and Inventions Agreement, a copy of which is attached hereto as Exhibit A.

 

X.      Resolution of Dispute

 

Any dispute regarding the agreement (including without limitation
its validity, interpretation, performance, enforcement, termination and damages) shall be determined in accordance with the laws
of the State of California, the United States of America.  Any action under this paragraph shall not preclude any party hereto
from seeking injunctive or other legal relief to which each party may be entitled.

 

XI.      Sole Agreement

 

This Agreement (including agreements executed in substantially
in the form of the exhibits attached hereto) supersedes all prior or contemporaneous written or oral understandings or agreements,
and may not be added to, modified, or waived, in whole or in part, except by a writing signed by the party against whom such addition,
modification or waiver is sought to be asserted.

 

XII.      Assignment

 

This Agreement and all of the provisions hereof shall be binding
upon and insure to the benefit of the parties hereto and their respective successors and permitted assigns and, except as otherwise
expressly provided herein, neither this Agreement, nor any of the rights, interests or obligations hereunder shall be assigned
by either of the parties hereto without the prior written consent of the other party.

 

XIII.      Notices

 

Any and all notices, requests and other communications required
or permitted hereunder shall be in writing, registered mail or by facsimile, to each of the parties at the addresses set forth
above or the numbers set forth below:

 

	The Director:	Mark A. Meyers
	 	19202 Cerro Villa Dr.
	 	Villa Park, CA  92861
	 	 
	ApolloMed:	Apollo Medical Holdings, Inc.
	 	700 N. Brand Blvd, Suite 450
	 	Glendale, CA  91203

 

Any such notice shall be deemed given when received and notice
given by registered mail shall be considered to have been given on the tenth (10th) day after having been sent in the manner provided
for above.

 

    	4

    	 

    

 

XIV.      Survival of Obligations

 

Notwithstanding the expiration of termination of this Agreement,
neither party hereto shall be released hereunder from any liability or obligation to the other which has already accrued as of
the time of such expiration or termination (including, without limitation, ApolloMed’s obligation to make any fees and expense
payments required pursuant to Section IV and/or ApolloMed’s indemnification and insurance obligations set forth in Section
V hereof) or which thereafter might accrue in respect of any act or omission of such party prior to such expiration or termination.

 

XV.      Attorneys’ Fees

 

If any legal action or other proceeding
is brought for the enforcement of this Agreement, or because of a dispute, breach or default in connection with any of the provisions
hereof, the successful or prevailing party (including a party successful or prevailing in defense) shall be entitled to recover
its actual attorneys’ fees and other costs incurred in that action or proceeding, in addition to any other relief to which
it may be entitled.

 

XV.      Severability

 

Any provision of this Agreement which is determined to be invalid
or unenforceable shall not affect the remainder of this Agreement, which shall remain in effect as though the invalid or unenforceable
provision had not been included herein, unless the removal of the invalid or unenforceable provision would substantially defeat
the intent, purpose or spirit of this Agreement.

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement
to be executed as of the date first written above.

 

	Director:	 	Apollo Medical Holdings, Inc.
	 	 	 	 	 
	Signature:	/s/ Mark A. Meyers	 	Signature:	/s/ Warren Hosseinion, M.D. 
	 	 	 	 	 
	Print Name:	Mark A. Meyers	 	Print Name:  	Warren Hosseinion, M.D.
	 	 	 	 	 
	 	 	 	Title:  	CEO

 

    	5

    	 

    

 

EXHIBIT PROPRIETARY INFORMATION AGREEMENT

 

THIS BOARD OF DIRECTORS PROPRIETARY INFORMATION AGREEMENT
(“Agreement”) is made and entered into this 15th day of October, 2012 by and between APOLLO MEDICAL
HOLDINGS, INC., a Delaware corporation (“ApolloMed”), and Mark A. Meyers (the “Director”).

 

RECITALS

 

WHEREAS, the Director has been elected to serve on the Board
of Directors of ApolloMed;

 

WHEREAS, the parties desire to assure the confidential status
of the information which may be disclosed by ApolloMed to the Director in connection with the Director serving on ApolloMed’s
Board of Directors;

 

NOW THEREFORE, in reliance upon and in consideration
of the following undertaking, the parties agree as follows:

 

AGREEMENT

 

1.      
Subject to the limitations set forth in Paragraph 2, all information disclosed by ApolloMed to the Director shall be deemed to
be "Proprietary Information".  In particular, Proprietary Information shall be deemed to include any information,
process, technique, algorithm, program, design, drawing, formula or test data relating to any research project, work in process,
future development, engineering, manufacturing, marketing, servicing, financing or personnel matter relating to ApolloMed, its
present or future products, sales, suppliers, customers, employees, investors, or business, whether or oral, written, graphic or
electronic form.

 

2.      
The term "Proprietary Information" shall not be deemed to include the following information: (i) information which is
now, or hereafter becomes, through no breach of this Agreement on the part of the Director, generally known or available to the
public; (ii) is known by the Director at the time of receiving such information; (iii) is hereafter furnished to the Director by
a third party, as a matter of right and without restriction on disclosure; or (iv) is the subject of a written permission to disclose
provided by ApolloMed.

 

3.      
The Director shall maintain in trust and confidence and not disclose to any third party or use for any unauthorized purpose any
Proprietary Information received from ApolloMed.  The Director may use such Proprietary Information only to the extent required
to accomplish the purposes of his position as a Director of ApolloMed.  The Director shall not use Proprietary Information
for any purpose or in any manner which would constitute a violation of any laws or regulations, including without limitation the
export control laws of the United States.  No other rights of licenses to trademarks, inventions, copyrights, or patents are
implied or granted under this Agreement.

 

4.      
Proprietary Information supplied shall not be reproduced in any form except as required to accomplish the intent of this Agreement.

 

5.      
The Director represents and warrants that he shall protect the Proprietary Information received with at least the same degree of
care used to protect his own Proprietary Information from unauthorized use or disclosure.

 

6.      
All Proprietary Information (including all copies thereof) shall remain in the property of ApolloMed, and shall be returned to
ApolloMed (or destroyed) after the Director's need for it has expired, or upon request of ApolloMed, and in any event, upon the
termination of that certain Board of Directors Agreement, of even date herewith, between ApolloMed and the Director (the “Director
Agreement”).

 

    	6

    	 

    

 

7.      
Notwithstanding any other provision of this Agreement, disclosure of Proprietary Information shall not be precluded if such disclosure:

 

(a)   is in response to a valid order of a court or
other governmental body of the United States or any political subdivision thereof; provided, however, that the Director shall first
have given ApolloMed notice of the Director’s receipt of such order and ApolloMed shall have had an opportunity to obtain
a protective order requiring that the Proprietary Information so disclosed be used only for the purpose for which the order was
issued;

 

(b)   is otherwise required by law; or

 

(c)   is otherwise necessary to establish rights or
enforce obligations under this Agreement, but only to the extent that any such disclosure is necessary.

 

8.      
Subject to the terms of this Paragraph, this Agreement shall continue in full force and effect during the term of the Director
Agreement. This Agreement may be terminated at any time upon thirty (30) days written notice to the other party.  The termination
of this Agreement shall not relieve the Director of the obligations imposed by Paragraphs 3, 4, 5 and 11 of this Agreement with
respect to Proprietary information disclosed prior to the effective date of such termination and the provisions of these Paragraphs
shall survive the termination of this Agreement for a period of eighteen (18) months from the date of such termination.

 

9.     This Agreement
shall be governed by the laws of the State of California as those laws are applied to contracts entered into and to be performed
entirely in California by California residents.

 

10.      This
Agreement contains the final, complete and exclusive agreement of the parties relative to the subject matter hereof and may not
be changed, modified, amended or supplemented except by a written instrument signed by both parties.

 

11.      Each
party hereby acknowledges and agrees that in the event of any breach of this Agreement by the Director, including, without limitation,
an actual or threatened disclosure of Proprietary Information without the prior express written consent of ApolloMed, ApolloMed
will suffer an irreparable injury, such that no remedy at law will afford it adequate protection against, or appropriate compensation
for, such injury.  Accordingly, each party hereby agrees that ApolloMed shall be entitled to specific performance of the Director's
obligations under this Agreement, as well as such further injunctive relief as may be granted by a court of competent jurisdiction.

 

	Director:	 	Apollo Medical Holdings, Inc.
	 	 	 	 	 
	Signature:  	/s/ Mark A. Meyers	 	Signature:	/s/ Warren Hosseinion, M.D.
	 	 	 	 	 
	Print Name: 	Mark A. Meyers	 	Print Name:	Warren Hosseinion, M.D.
	 	 	 	 	 
	 	 	 	Title:	CEO

 

    	7

    	 

    

 

EXHIBIT B

 

INDEMNIFICATION
AGREEMENT

 

INDEMNIFICATION AGREEMENT (this “Agreement”)
dated as of October 15th, 2012, by and among APOLLO MEDICAL HOLDINGS, INC., a Delaware corporation (the “Company”)
and the indemnitees listed on the signature pages hereto (individually, as “Indemnitee” and, collectively, the “Indemnitees”).

 

RECITALS

 

A.           The
Company and Indemnitees recognize the continued difficulty in obtaining liability insurance for its directors, officers, employees,
stockholders, controlling persons, agents and fiduciaries, the significant increases in the cost of such insurance and the general
reductions in the coverage of such insurance.

 

B.           The
Company and Indemnitees further recognize the substantial increase in corporate litigation in general, which subjects directors,
officers, employees, controlling persons, stockholders, agents and fiduciaries to expensive litigation risks at the same time as
the availability and coverage of liability insurance has been severely limited.

 

C.           The
Indemnitees do not regard the current protection available as adequate under the present circumstances, and Indemnitees and other
directors, officers, employees, stockholders, controlling persons, agents and fiduciaries of the Company may not be willing to
serve in such capacities without additional protection.

 

D.           The
Company (i) desires to attract and retain highly qualified individuals and entities, such as Indemnitees, to serve the Company
and, in part, in order to induce each Indemnitee to be involved with the Company and (ii) wishes to provide for the indemnification
and advancing of expenses to each Indemnitee to the maximum extent permitted by law.

 

E.           In
view of the considerations set forth above, the Company desires that each Indemnitee be indemnified by the Company as set forth
herein.

 

    	8

    	 

    

 

NOW, THEREFORE, the Company and each Indemnitee
hereby agree as follows:

 

1.       Indemnification

 

a.        Indemnification
of Expenses. The Company shall indemnify and hold harmless each Indemnitee (including its respective directors, officers,
partners, former partners, members, former members, employees, agents and spouse, as applicable) and each person who controls
any of them or who may be liable within the meaning of Section 15 of the Securities Act of 1933, as amended (the “Securities
Act”), or Section 20 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to the fullest
extent permitted by law if such Indemnitee was or is or becomes a party to or witness or other participant in, or is threatened
to be made a party to or witness or other participant in, any threatened, pending or completed action, suit, proceeding or alternative
dispute resolution mechanism, or any hearing, inquiry or investigation that such Indemnitee believes might lead to the institution
of any such action, suit, proceeding or alternative dispute resolution mechanism, whether civil, criminal, administrative, investigative
or other (hereinafter a “Claim”) by reason of (or arising in part or in whole out of) any event or occurrence related
to the fact that Indemnitee is or was or may be deemed a director, officer, stockholder, employee, controlling person, agent or
fiduciary of the Company, or any subsidiary of the Company, or is or was or may be deemed to be serving at the request of the
Company as a director, officer, stockholder, employee, controlling person, agent or fiduciary of another corporation, partnership,
limited liability company, joint venture, trust or other enterprise, or by reason of any action or inaction on the part of such
Indemnitee while serving in such capacity including, without limitation, any and all losses, claims, damages, expenses and liabilities,
joint or several (including any investigation, legal and other expenses incurred in connection with, and any amount paid in settlement
of, any action, suit, proceeding or any claim asserted) under the Securities Act, the Exchange Act or other federal or state statutory
law or regulation, at common law or otherwise or which relate directly or indirectly to the registration, purchase, sale or ownership
of any securities of the Company or to any fiduciary obligation owed with respect thereto or as a direct or indirect result of
any Claim made by any stockholder of the Company against an Indemnitee and arising out of or related to any round of financing
of the Company (including but not limited to Claims regarding non-participation, or non-pro rata participation, in such round
by such stockholder), or made by a third party against an Indemnitee based on any misstatement or omission of a material fact
by the Company in violation of any duty of disclosure imposed on the Company by federal or state securities or common laws (hereinafter
an “Indemnification Event”) against any and all expenses (including attorneys’ fees and all other costs, expenses
and obligations incurred in connection with investigating, defending a witness in or participating in (including on appeal), or
preparing to defend, be a witness in or participate in, any such action, suit, proceeding, alternative dispute resolution mechanism,
hearing, inquiry or investigation), judgments, fines, penalties and amounts paid in settlement (if, and only if, such settlement
is approved in advance by the Company, which approval shall not be unreasonably withheld) of such Claim and any federal, state,
local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement
(collectively, hereinafter “Expenses”), including all interest, assessments and other charges paid or payable in connection
with or in respect of such Expenses. Such payment of Expenses shall be made by the Company as soon as practicable but in any event
no later than ten (10) days after written demand by the Indemnitee therefor is presented to the Company.

 

b.        Reviewing
Party. Notwithstanding the foregoing, (i) the obligations of the Company under Section 1(a) shall be subject to the condition
that the Reviewing Party (as described in Section 10(e) hereof) shall not have determined (in a written opinion, in any case in
which the Independent Legal Counsel referred to in Section 1(e) hereof is involved) that Indemnitee would not be permitted to
be indemnified under applicable law, and (ii) each Indemnitee acknowledges and agrees that the obligation of the Company to make
an advance payment of Expenses to Indemnitee pursuant to Section 2(a) (an “Expense Advance”) shall be subject to the
condition that, if, when and to the extent that the Reviewing Party determines that Indemnitee would not be permitted to be so
indemnified under applicable law, the Company shall be entitled to be reimbursed by Indemnitee (who hereby agrees to reimburse
the Company) for all such amounts theretofore paid; provided, however, that if Indemnitee has commenced or thereafter commences
legal proceedings in a court of competent jurisdiction to secure a determination that Indemnitee should be indemnified under applicable
law, any determination made by the Reviewing Party that Indemnitee would not be permitted to be indemnified under applicable law
shall not be binding and Indemnitee shall not be required to reimburse the Company for any Expense Advance until a final judicial
determination is made with respect thereto (as to which all rights of appeal therefrom have been exhausted or lapsed). Indemnitee’s
obligation to reimburse the Company for any Expense Advance shall be unsecured and no interest shall be charged thereon. If there
has not been a Change in Control (as defined in Section 10(c) hereof), the Reviewing Party shall be selected by the Board of Directors,
and if there has been such a Change in Control (other than a Change in Control which has been approved by a majority of the Company’s
Board of Directors who were directors immediately prior to such Change in Control), the Reviewing Party shall be the Independent
Legal Counsel referred to in Section 1(e) hereof. If there has been no determination by the Reviewing Party or if the Reviewing
Party determines that Indemnitee substantively would not be permitted to be indemnified in whole or in part under applicable law,
Indemnitee shall have the right to commence litigation seeking an initial determination by the court or challenging any such determination
by the Reviewing Party or any aspect thereof, including the legal or factual bases therefor, and the Company hereby consents to
service of process and to appear in any such proceeding. Any determination by the Reviewing Party otherwise shall be conclusive
and binding on the Company and Indemnitee.

 

    	9

    	 

    

 

c.        Contribution.
If the indemnification provided for in Section 1(a) above for any reason is held by a court of competent jurisdiction to be unavailable
to an Indemnitee in respect of any losses, claims, damages, expenses or liabilities referred to therein, then the Company, in
lieu of indemnifying such Indemnitee thereunder, shall contribute to the amount paid or payable by such Indemnitee as a result
of such losses, claims, damages, expenses or liabilities (i) in such proportion as is appropriate to reflect the relative benefits
received by the Company and the Indemnitee, or (ii) if the allocation provided by clause (i) above is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the
relative fault of the Company and the Indemnitee in connection with the action or inaction which resulted in such losses, claims,
damages, expenses or liabilities, as well as any other relevant equitable considerations. In connection with the registration
of the Company’s securities, the relative benefits received by the Company and the Indemnitee shall be deemed to be in the
same respective proportions that the net proceeds from the offering (before deducting expenses) received by the Company and the
Indemnitee, in each case as set forth in the table on the cover page of the applicable prospectus, bear to the aggregate public
offering price of the securities so offered. The relative fault of the Company and the Indemnitee shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission
to state a material fact relates to information supplied by the Company or the Indemnitee and the parties’ relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission.

 

The Company and the Indemnitee agree that
it would not be just and equitable if contribution pursuant to this Section 1(c) were determined by pro rata or per capita allocation
or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately
preceding paragraph. In connection with the registration of the Company’s securities, in no event shall Indemnitee be required
to contribute any amount under this Section 1(c) in excess of the lesser of (i) that proportion of the total of such losses, claims,
damages or liabilities indemnified against equal to the proportion of the total securities sold under such registration statement
which is being sold by such Indemnitee or (ii) the proceeds received by such Indemnitee from its sale of securities under such
registration statement. No person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) shall be entitled to contribution from any person who was not found guilty of such fraudulent misrepresentation.

 

d.        Survival
Regardless of Investigation. The indemnification and contribution provided for in this Section 1 will remain in full force
and effect regardless of any investigation made by or on behalf of the Indemnitee or any officer, director, employee, agent or
controlling person of the Indemnitee.

 

e.        Change
in Control. The Company agrees that if there is a Change in Control of the Company (other than a Change in Control which has
been approved by a majority of the Company’s Board of Directors who were directors immediately prior to such Change in Control)
then, with respect to all matters thereafter arising concerning the rights of Indemnitee to payments of Expenses under this Agreement
or any other agreement or under the Company’s Certificate of Incorporation, as amended (the “Certificate”),
or Bylaws as now or hereafter in effect, Independent Legal Counsel (as defined in Section 10(d) hereof) shall be selected by the
Indemnitee and approved by the Company (which approval shall not be unreasonably withheld). Such counsel, among other things,
shall render its written opinion to the Company and Indemnitee as to whether and to what extent Indemnitee would be permitted
to be indemnified under applicable law. The Company agrees to abide by such opinion and to pay the reasonable fees of the Independent
Legal Counsel referred to above and to fully indemnify such counsel against any and all expenses (including attorneys’ fees),
claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

 

f.         Mandatory
Payment of Expenses. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee has been successful
on the merits or otherwise, including, without limitation, the dismissal of an action without prejudice, in the defense of any
action, suit, proceeding, inquiry or investigation referred to in Section 1(a) hereof or in the defense of any claim, issue or
matter therein, each Indemnitee shall be indemnified against all Expenses incurred by such Indemnitee in connection herewith.

 

    	10

    	 

    

 

2.       Expenses;
Indemnification Procedure.

 

a.        Advancement
of Expenses. The Company shall advance all Expenses incurred by Indemnitee. The advances to be made hereunder shall be paid
by the Company to Indemnitee as soon as practicable but in any event no later than fifteen (15) days after written demand by such
Indemnitee therefor to the Company.

 

b.        Notice/Cooperation
by Indemnitee. Indemnitee shall give the Company notice as soon as practicable of any Claim made against Indemnitee for which
indemnification will or could be sought under this Agreement. Notice to the Company shall be directed to the Chief Executive Officer
of the Company at the address shown on the signature page of this Agreement (or such other address as the Company shall designate
in writing to Indemnitee).

 

c.        No
Presumptions; Burden of Proof. For purposes of this Agreement, the termination of any Claim by judgment, order, settlement
(whether with or without court approval) or conviction, or upon a plea of nolo contendere, or its equivalent, shall not create
a presumption that Indemnitee did not meet any particular standard of conduct or have any particular belief or that a court has
determined that indemnification is not permitted by applicable law. In addition, neither the failure of the Reviewing Party to
have made a determination as to whether Indemnitee has met any particular standard of conduct or had any particular belief, nor
an actual determination by the Reviewing Party that Indemnitee has not met such standard of conduct or did not have such belief,
prior to the commencement of legal proceedings by Indemnitee to secure a judicial determination that Indemnitee should be indemnified
under applicable law, shall be a defense to Indemnitee’s claim or create a presumption that Indemnitee has not met any particular
standard of conduct or did not have any particular belief. In connection with any determination by the Reviewing Party or otherwise
as to whether Indemnitee is entitled to be indemnified hereunder, the burden of proof shall be on the Company to establish that
Indemnitee is not so entitled.

 

d.        Notice
to Insurers. If, at the time of the receipt by the Company of a notice of a Claim pursuant to Section 2(b) hereof, the Company
has liability insurance in effect which may cover such Claim, the Company shall give prompt written notice of the commencement
of such Claim to the insurers in accordance with the procedures set forth in each of the policies. The Company shall thereafter
take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result
of such action, suit, proceeding, inquiry or investigation in accordance with the terms of such policies.

 

e.        Selection
of Counsel. In the event the Company shall be obligated hereunder to pay the Expenses of any Claim, the Company shall be entitled
to assume the defense of such Claim, with counsel reasonably approved by the applicable Indemnitee, upon the delivery to such
Indemnitee of written notice of its election to do so. After delivery of such notice, approval of such counsel by the Indemnitee
and the retention of such counsel by the Company, the Company will not be liable to such Indemnitee under this Agreement for any
fees of counsel subsequently incurred by such Indemnitee with respect to the same Claim; provided that, (i) the Indemnitee shall
have the right to employ such Indemnitee’s counsel in any such Claim at the Indemnitee’s expense; (ii) the Indemnitee
shall have the right to employ its own counsel in connection with any such proceeding, at the expense of the Company, if such
counsel serves in a review, observer, advice and counseling capacity and does not otherwise materially control or participate
in the defense of such proceeding; and (iii) if (A) the employment of counsel by the Indemnitee has been previously authorized
by the Company, (B) such Indemnitee shall have reasonably concluded that there is a conflict of interest between the Company and
such Indemnitee in the conduct of any such defense, or (C) the Company shall not continue to retain such counsel to defend such
Claim, then the fees and expenses of the Indemnitee’s counsel shall be at the expense of the Company.

 

    	11

    	 

    

 

3.       Additional
Indemnification Rights; Nonexclusivity.

 

a.        Scope.
The Company hereby agrees to indemnify Indemnitee to the fullest extent permitted by law, even if such indemnification is not
specifically authorized by the other provisions of this Agreement or any other agreement, the Certificate, the Company’s
Bylaws or by statute. In the event of any change after the date of this Agreement in any applicable law, statute or rule which
expands the right of a Delaware corporation to indemnify a member of its Board of Directors or an officer, stockholder, employee,
controlling person, agent or fiduciary, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the
greater benefits afforded by such change. In the event of any change in any applicable law, statute or rule which narrows the
right of a Delaware corporation to indemnify a member of its Board of Directors or an officer, employee, agent or fiduciary, such
change, to the extent not otherwise required by such law, statute or rule to be applied to this Agreement, shall have no effect
on this Agreement or the parties’ rights and obligations hereunder except as set forth in Section 8(a) hereof.

 

b.       Nonexclusivity.
Notwithstanding anything in this Agreement, the indemnification provided by this Agreement shall be in addition to any rights
to which Indemnitee may be entitled under the Certificate, the Company’s Bylaws, any agreement, any vote of stockholders
or disinterested directors, the laws of the State of Delaware, or otherwise. Notwithstanding anything in this Agreement, the indemnification
provided under this Agreement shall continue as to each Indemnitee for any action such Indemnitee took or did not take while serving
in an indemnified capacity even though the Indemnitee may have ceased to serve in such capacity and such indemnification shall
inure to the benefit of each Indemnitee from and after Indemnitee’s first day of service as a director with the Company
or affiliation with a director from and after the date such director commences services as a director with the Company.

 

4.       No
Duplication of Payments. The Company shall not be liable under this Agreement to make any payment in connection with any Claim
made against any Indemnitee to the extent such Indemnitee has otherwise actually received payment (under any insurance policy,
Certificate, Bylaws or otherwise) of the amounts otherwise indemnifiable hereunder.

 

5.       Partial
Indemnification. If any Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for
any portion of Expenses incurred in connection with any Claim, but not, however, for all of the total amount thereof, the Company
shall nevertheless indemnify Indemnitee for the portion of such Expenses to which such Indemnitee is entitled.

 

6.       Mutual
Acknowledgement. The Company and each Indemnitee acknowledge that in certain instances, Federal law or applicable public policy
may prohibit the Company from indemnifying its directors, officers, employees, controlling persons, agents or fiduciaries under
this Agreement or otherwise.

 

7.       Liability
Insurance. During any period of time any Indemnitee is entitled to indemnification rights under this Agreement, the Company
shall maintain liability insurance applicable to directors, officers, employees, control persons, agents or fiduciaries, each
Indemnitee shall be covered by such policies in such a manner as to provide Indemnitee the same rights and benefits as are accorded
to the most favorably insured of the Company’s directors, if such Indemnitee is a director, or of the Company’s officers,
if such Indemnitee is not a director of the Company but is an officer; or of the Company’s key employees, controlling persons,
agents or fiduciaries, if such Indemnitee is not an officer or director but is a key employee, agent, control person, or fiduciary.
Said liability insurance shall provide coverage amounts of no less than those specified in Schedule A attached hereto and be held
with an insurance carrier which is the Board of Directors of the Company believes is of financial sound condition.

 

8.       Exceptions.
Any other provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement:

 

a.        Claims
Under Section 16(b). To indemnify any Indemnitee for expenses and the payment of profits arising from the purchase and sale by
such Indemnitee of securities in violation of Section 16(b) of the Exchange Act or any similar successor statute;

 

b.        Unlawful
Indemnification. To indemnify an Indemnitee if a final decision by a court having jurisdiction in the matter shall determine that
such indemnification is not lawful;

 

c.        Fraud.
To indemnify an Indemnitee if a final decision by a court having jurisdiction in the matter shall determine that the Indemnitee
has committed fraud on the Company; or

 

    	12

    	 

    

 

d.        Insurance.
To indemnify any Indemnitee for which payment is actually and fully made to Indemnitee under a valid and collectible insurance
policy.

 

9.       Period
of Limitations. No legal action shall be brought and no cause of action shall be asserted by or in the right of the Company
against any Indemnitee, any Indemnitee’s estate, spouse, heirs, executors or personal or legal representatives after the
expiration of five (5) years from the date of accrual of such cause of action, and any claim or cause of action of the Company
shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such five (5) year period;
provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action, such shorter
period shall govern.

 

10.      Construction
of Certain Phrases.

 

a.        For
purposes of this Agreement, references to the “Company” shall include, in addition to the resulting corporation, any
constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate
existence had continued, would have had power and authority to indemnify its directors, officers, employees, agents or fiduciaries,
so that if Indemnitee is or was or may be deemed a director, officer, employee, agent, control person, or fiduciary of such constituent
corporation, or is or was or may be deemed to be serving at the request of such constituent corporation as a director, officer,
employee, control person, agent or fiduciary of another corporation, partnership, joint venture, employee benefit plan, trust or
other enterprise, each Indemnitee shall stand in the same position under the provisions of this Agreement with respect to the resulting
or surviving corporation as each Indemnitee would have with respect to such constituent corporation if its separate existence had
continued.

 

b.        For
purposes of this Agreement, references to “other enterprises” shall include employee benefit plans; references to “fines”
shall include any excise taxes assessed on any Indemnitee with respect to an employee benefit plan; and references to “serving
at the request of the Company” shall include any service as a director, officer, employee, agent or fiduciary of the Company
which imposes duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect to an employee
benefit plan, its participants or its beneficiaries; and if any Indemnitee acted in good faith and in a manner such Indemnitee
reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan, such Indemnitee shall
be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

 

c.        For
purposes of this Agreement a “Change in Control” shall be deemed to have occurred if (i) any “person” (as
such term is used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act), other than a trustee or other fiduciary holding securities
under an employee benefit plan of the Company or a corporation owned directly or indirectly by the stockholders of the Company
in substantially the same proportions as their ownership of stock of the Company, (A) who is or becomes the beneficial owner, directly
or indirectly, of securities of the Company representing 20% or more of the combined voting power of the Company’s then outstanding
Voting Securities, increases his beneficial ownership of such securities by 5% or more over the percentage so owned by such person,
or (B) becomes the “beneficial owner” (as defined in Rule 13d-3 under said Exchange Act), directly or indirectly, of
securities of the Company representing more than 30% of the total voting power represented by the Company’s then outstanding
Voting Securities, (ii) during any period of two consecutive years, individuals who at the beginning of such period constitute
the Board of Directors of the Company and any new director whose election by the Board of Directors or nomination for election
by the Company’s stockholders was approved by a vote of at least two-thirds (2/3) of the directors then still in office who
either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease
for any reason to constitute a majority thereof, or (iii) the stockholders of the Company approve a merger or consolidation of
the Company with any other corporation other than a merger or consolidation which would result in the Voting Securities of the
Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into
Voting Securities of the surviving entity) at least two-thirds (2/3) of the total voting power represented by the Voting Securities
of the Company or such surviving entity outstanding immediately after such merger or consolidation, or the stockholders of the
Company approve a plan of complete liquidation of the Company or an agreement for the sale or disposition by the Company of (in
one transaction or a series of transactions) all or substantially all of the Company’s assets.

 

    	13

    	 

    

 

d.        For
purposes of this Agreement, “Independent Legal Counsel” shall mean an attorney or firm of attorneys, selected in accordance
with the provisions of Section 1(e) hereof, who shall not have otherwise performed services for the Company or any Indemnitee within
the last three (3) years (other than with respect to matters concerning the right of any Indemnitee under this Agreement, or of
other indemnitees under similar indemnity agreements).

 

e.        For
purposes of this Agreement, a “Reviewing Party” shall mean any appropriate person or body consisting of a member or
members of the Company’s Board of Directors or any other person or body appointed by the Board of Directors who is not a
party to the particular Claim for which Indemnitee is seeking indemnification, or Independent Legal Counsel.

 

f.         For
purposes of this Agreement, “Voting Securities” shall mean any securities of the Company that vote generally in the
election of directors.

 

11.         Counterparts.
This Agreement may be executed in one or more counterparts, each of which shall constitute an original.

 

12.         Binding
Effect; Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the
parties hereto and their respective successors, assigns, including any direct or indirect successor by purchase, merger, consolidation
or otherwise to all or substantially all of the business and/or assets of the Company, spouses, heirs, and personal and legal representatives.
The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise)
to all, substantially all, or a substantial part, of the business and/or assets of the Company, by written agreement in form and
substance satisfactory to each Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the
same extent that the Company would be required to perform if no such succession had taken place. This Agreement shall continue
in effect with respect to Claims relating to Indemnifiable Events regardless of whether any Indemnitee continues to serve as a
director, officer, employee, agent, controlling person, or fiduciary of the Company or of any other enterprise, including subsidiaries
of the Company, at the Company’s request.

 

13.         Attorneys’
Fees. In the event that any action is instituted by an Indemnitee under this Agreement or under any liability insurance policies
maintained by the Company to enforce or interpret any of the terms hereof or thereof, any Indemnitee shall be entitled to be paid
all Expenses incurred by such Indemnitee with respect to such action if such Indemnitee is ultimately successful in such action.
In the event of an action instituted by or in the name of the Company under this Agreement to enforce or interpret any of the terms
of this Agreement, the Indemnitee shall be entitled to be paid Expenses incurred by such Indemnitee in defense of such action (including
costs and expenses incurred with respect to Indemnitee counterclaims and cross-claims made in such action), and shall be entitled
to the advancement of Expenses with respect to such action, in each case only to the extent that such Indemnitee is ultimately
successful in such action.

 

14.         Notice.
All notices and other communications required or permitted hereunder shall be in writing, shall be effective when given, and shall
in any event be deemed to be given (a) five (5) days after deposit with the U.S. Postal Service or other applicable postal service,
if delivered by first class mail, postage prepaid, (b) upon delivery, if delivered by hand, (c) one business day after the business
day of deposit with Federal Express or similar overnight courier, freight prepaid, or (d) one day after the business day of delivery
by facsimile transmission, if deliverable by facsimile transmission, with copy by first class mail, postage prepaid, and shall
be addressed if to Indemnitee, at each Indemnitee’s address as set forth beneath the Indemnitee’s signature to this
Agreement and if to the Company at the address of its principal corporate offices (attention: Secretary) or at such other address
as such party may designate by ten (10) days’ advance written notice to the other party hereto.

 

    	14

    	 

    

 

15.         Severability.
The provisions of this Agreement shall be severable in the event that any of the provisions hereof (including any provision within
a single section, paragraph or sentence) are held by a court of competent jurisdiction to be invalid, void or otherwise unenforceable,
and the remaining provisions shall remain enforceable to the fullest extent permitted by law. Furthermore, to the fullest extent
possible, the provisions of this Agreement (including, without limitations, each portion of this Agreement containing any provision
held to be invalid, void or otherwise unenforceable, that is not itself invalid, void or unenforceable) shall be construed so as
to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.

 

16.         Choice
of Law. This Agreement shall be governed by and its provisions construed and enforced in accordance with the laws of the State
of Delaware, as applied to contracts between Delaware residents, entered into and to be performed entirely within the State of
Delaware, without regard to the conflict of laws principles thereof.

 

17.         Subrogation.
In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights
of recovery of Indemnitee who shall execute all documents required and shall do all acts that may be necessary to secure such rights
and to enable the Company effectively to bring suit to enforce such rights.

 

18.         Amendment
and Termination. No amendment, modification, termination or cancellation of this Agreement shall be effective unless it is
in writing signed by the parties to be bound thereby. Notice of same shall be provided to all parties hereto. No waiver of any
of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not
similar) nor shall such waiver constitute a continuing waiver.

 

19.         Corporate
Authority. The Board of Directors of the Company and its stockholders in accordance with Delaware law have approved the terms
of this Agreement.

 

(Remainder of page intentionally left blank)

 

    	15

    	 

    

 

IN WITNESS
WHEREOF, the parties hereto have executed this Indemnification Agreement on and as of the day and year first above written.

 

	 	APOLLO MEDICAL HOLDINGS, INC.,
	 	a Delaware corporation
	 	 
	 	By: /s/ WARREN HOSSEINION, M.D.,
	 	Warren Hosseinion, M.D.
	 	 
	 	“Indemnitees”
	 	 
	 	By: /s/ Mark A. Meyers
	 	Mark A. Meyers

 

    	16BOARD OF DIRECTORS AGREEMENT

 

This Board of Directors Agreement (“Agreement”)
made as of March 7, 2012 by and between Apollo Medical Holdings, Inc., with its principal place of business at 700 N. Brand Blvd,
Suite 450, Glendale, California, 91203 (“ApolloMed”) and Gary Augusta, with an address of 25682 Rolling Hills Rd.,
Laguna Hills, CA 92653, (the “Director”) provides for director services, according to the following terms and conditions:

 

I.      Services Provided

 

ApolloMed agrees to engage the Director to serve as a member
of the Board of Directors of ApolloMed and to provide those services required of a director under ApolloMed’s Certificate
of Incorporation and Bylaws, as both may be amended from time, to time (“Articles and Bylaws”) and under the General
Corporation Law of Delaware, the federal securities laws and other state and federal laws and regulations, as applicable.

 

II.      Nature of Relationship

 

The Director is an independent contractor and will not be deemed
an employee of ApolloMed for purposes of employee benefits, income tax withholding, F.I.C.A. taxes, unemployment benefits or otherwise. 
The Director shall not enter into any agreement or incur any obligations on ApolloMed’s behalf.

 

ApolloMed will supply, at no cost to the Director:  periodic
briefings on the business, director packages for each board and committee meeting, copies of minutes of meetings and any other
materials that are required under ApolloMed’s Articles and Bylaws or the charter of any committee of the board on which the
Director serves and any other materials which may, by mutual agreement, be necessary for performing the services requested under
this Agreement.

 

III.      Director’s Warranties

 

The Director warrants that no other party has exclusive rights
to his services in the specific areas in which ApolloMed is conducting business and that the Director is in no way compromising
any rights or trust between any other party and the Director or creating a conflict of interest as a result of his participation
on the Board of Directors of ApolloMed.  The Director also warrants that so long as the Director serves on the board of the
directors of ApolloMed, the Director will not enter into another agreement that will create a conflict of interest with this Agreement. 
The Director further warrants that he will comply with all applicable state and federal laws and regulations, as applicable, including
Sections 10 and 16 of the Securities and Exchange Act of 1934.

 

Throughout the term of this Agreement, the Director agrees he
will not, without obtaining ApolloMed’s prior written consent, directly or indirectly engage or prepare to engage in any
activity in competition with any ApolloMed business or product, including products in the development stage, accept employment
or provide services to (including service as a member of a board of directors), or establish a business in competition with ApolloMed.

 

IV.      Compensation

 

A.  Cash Fee

 

During the term of this Agreement, ApolloMed shall pay the Director
a nonrefundable fee of $1,000 per board of director meeting in consideration for the Director providing the services described
in Section I which shall compensate him for all time spent preparing for, travelling to (if applicable) and attending board of
director meetings; provided, however, that if any board meetings or duties require out-of-town travel time, such additional travel
time may be billed at the rate set forth in subparagraph C of Section IV below.  This cash fee may be revised by action of
ApolloMed’s Board of Directors from time to time.  Such revision shall be effective as of the date specified in the
resolution for payments not yet earned and need not be documented by an amendment to this Agreement.

 

    	1

    	 

    

 

B.    Equity Compensation

 

Purchase of Shares.  Mr. Augusta hereby purchases,
and the Corporation hereby sells to Mr. Augusta, 400,000 shares of Common Stock (the “Purchased Shares”) at
a purchase price of $0.001 per share (the “Purchase Price”).  Concurrently with the execution of this
Agreement, Mr. Augusta shall pay the Purchase Price for the Purchased Shares in cash.

 

Restricted Securities.  Mr. Augusta hereby
confirms that he has been informed that the Purchased Shares are restricted securities under the Securities Act of 1933 (the “1933
Act”) and may not be resold or transferred unless the Purchased Shares are first registered under the federal securities
laws or unless an exemption from such registration is available.  Accordingly, Mr. Augusta hereby acknowledges that he
is prepared to hold the Purchased Shares for an indefinite period and that Mr. Augusta is aware that Rule 144 of the Securities
and Exchange Commission issued under the 1933 Act is not presently available to exempt the sale of the Purchased Shares from the
registration requirements of the 1933 Act.  Prior to his acquisition of the Purchased Shares, Mr. Augusta acquired sufficient
information about the Corporation to reach an informed knowledgeable decision to acquire the Purchased Shares.  Mr. Augusta
has such knowledge and experience in financial and business matters as to make Mr. Augusta capable of utilizing said information
to evaluate the risks of the prospective investment and to make an informed investment decision.  Mr. Augusta is able
to bear the economic risk of Mr. Augusta’s investment in the Purchased Stock.

 

Disposition of Shares.  Mr. Augusta hereby
agrees that he shall make no disposition of the Purchased Shares (other than a permitted transfer as described below) unless and
until he shall have notified the Corporation of the proposed disposition and, if requested by the Corporation, Mr. Augusta shall
have provided the Corporation an opinion of counsel in form and substance satisfactory to the Corporation, that (i) the proposed
disposition does not require registration of the Purchased Shares under the 1933 Act or (ii) all appropriate action necessary
for compliance with the registration requirements of the 1933 Act or of any exemption from registration available under the 1933
Act (including Rule 144) has been taken.

 

The Corporation shall not be required (i) to transfer on
its books any Purchased Shares that have been sold or transferred in violation of the provisions of this section or (ii) to
treat as the owner of the Purchased Shares, or otherwise to accord voting or dividend rights to, any transferee to whom the Purchased
Shares have been transferred in contravention of the Directors Agreement, including this Amendment.

 

Restrictive Legends.  In order to reflect the
restrictions on disposition of the Purchased Shares, the stock certificates for the Purchased Shares will be endorsed with restrictive
legends, including one or both of the following legends:

 

“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”).  THE SHARES MAY NOT BE SOLD OR OFFERED
FOR SALE IN THE ABSENCE OF (I) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SHARES UNDER SUCH ACT, OR (II) AN OPINION
OF COUNSEL SATISFACTORY TO THE CORPORATION THAT REGISTRATION UNDER SUCH ACT IS NOT REQUIRED WITH RESPECT TO SUCH SALE OR OFFER.

 

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE
TERMS AND CONDITIONS OF A CERTAIN BOARD OF DIRECTORS AGREEMENT, AS AMENDED, INCLUDING A REPURCHASE RIGHT, AND SUCH AGREEMENT IS
ON FILE AT THE CORPORTATION’S PRINCIPAL OFFICE AND MAY BE INSPECTED DURING NORMAL BUSINESS HOURS.”

 

    	2

    	 

    

 

If required by the authorities of any state in connection with
the issuance of the Purchased Shares, the legend or legends required by such state authorities shall also be endorsed on all such
certificates.

 

Mr. Augusta Rights.  Until such time as the
Corporation actually exercises its Repurchase Rights under this Amendment, Mr. Augusta (or any successor in interest) shall have
all the rights of a shareholder (including voting and dividend rights) with respect to the Purchased Shares, subject, however,
to the transfer restrictions set forth below.

 

Section 83(b) Election.  Mr. Augusta understands
that under Section 83 of the Internal Revenue Code of 1986, as amended (the “Code”), the difference between
the Purchase Price paid for the Purchased Shares and their fair market value on the date any forfeiture restrictions applicable
to such shares lapse will be reportable as ordinary income at that time.  For this purpose, the term “forfeiture
restrictions” includes the right of the Corporation to repurchase the Purchased Shares pursuant to its Repurchase Right under
this Amendment.  Mr. Augusta understands that he may elect to be taxed at the time the Purchased Shares are acquired
hereunder to the extent the fair market value of the Purchased Shares exceeds the Purchase Price rather than when and as such Purchased
Shares cease to be subject to such forfeiture restrictions, by filing an election under Section 83(b) of the Code with the
I.R.S. within thirty (30) days after the date of purchase hereunder.  If the fair market value of the Purchased Shares
at the date of purchase equals (or is less than) the Purchase Price paid (and thus no tax is payable), the election must be made
to avoid adverse tax consequences in the future.  The form for making this election is attached as Exhibit C hereto.  Mr.
Augusta understands that failure to make this filing within the thirty (30) day period will result in the recognition of ordinary
income by Mr. Augusta (in the event the fair market value of the Purchased Shares increases after the date of purchase) as the
forfeiture restrictions lapse.  MR. AUGUSTA IS URGED TO SEEK ADVICE FROM HIS TAX ADVISOR AS TO WHETHER OR NOT TO MAKE
A SECTION 83(b) ELECTION AND THE RAMIFICATIONS OF MAKING SUCH AN ELECTION.  IN PROVIDING THE FORM ATTACHED AS EXHIBIT
A, THE COMPANY MAKES NO REPRESENTATIONS AS TO WHETHER THE SECTION 83(b) ELECTION SHOULD BE MADE BY EMPLOYEE.  MR. AUGUSTA
ACKNOWLEDGES THAT IT IS HIS SOLE RESPONSIBILITY, AND NOT THE CORPORATION’S, TO FILE A TIMELY ELECTION UNDER SECTION 83(b),
EVEN IF HE REQUESTS THE CORPORATION OR ITS REPRESENTATIVES TO MAKE THIS FILING ON HIS BEHALF.

 

Transfer Restrictions.  Mr. Augusta shall not
transfer, assign, encumber, or otherwise dispose of any of the Purchased Shares that are subject to the Corporation’s Repurchase
Right.  Such restrictions on transfer, however, shall not be applicable to a transfer of title to the Purchased Shares
effected pursuant to Mr. Augusta’s will or the laws of intestate succession provided that the transferee, as a condition
precedent to the validity of such transfer, acknowledges in writing to the Corporation that such transferee is bound by the provisions
of this Amendment and that the transferred shares are subject to the Corporation’s Repurchase Right granted hereunder, to
the same extent such shares would be so subject if retained by Mr. Augusta.

 

Grant of Repurchase Right.  The Corporation
is hereby granted the right (the “Repurchase Right”), at any time during the sixty (60) day period following
the first date that Mr. Augusta is no longer a director of the Corporation (the “Repurchase Date”), to elect
to repurchase all or (at the discretion of the Corporation) any portion of the Purchased Shares in which Mr. Augusta has not acquired
a vested interest in accordance with the vesting provisions set forth below (such shares to be hereinafter called the “Unvested
Shares”) at a purchase price of $.001 per share.

 

Exercise of the Repurchase Right.  The Repurchase
Right shall be exercisable by written notice delivered to Mr. Augusta prior to the expiration of the sixty (60) day period following
the Repurchase Date.  The notice shall indicate the number of Unvested Shares to be repurchased and the date on which
the repurchase is to be effected, such date to be not more than thirty (30) days after the date of notice.  The Corporation
shall, concurrently with the receipt of such stock certificates from Mr. Augusta, pay to Mr. Augusta in cash or cash equivalents,
an amount equal to the Purchase Price with respect to the Unvested Shares that are to be repurchased.

 

    	3

    	 

    

 

Vesting of Purchased Shares; Termination of the Repurchase
Right.  Notwithstanding any other provision in this Agreement to the contrary, the Corporation’s Repurchase
Right shall terminate, and the Purchased Shares shall become fully vested, with respect to 400,000/36 of the Purchased Shares on
the last day of each month (each, a “Vesting Date”), starting on January 1, 2012 and ending on December
31, 2014, provided that Mr. Augusta continuously serves as director through that Vesting Date.  If any installment includes
a fraction of a share, the fraction shall be carried forward and added to subsequent installments. The Repurchase Right shall terminate
with respect to any Unvested Shares for which it is not exercised within 60 days of the Repurchase Date.

 

Additional Shares or Substituted Securities.  In
the event of any stock dividend, stock split, recapitalization or other change affecting the Corporation’s outstanding common
stock as a class effected without receipt of consideration, then any new, substituted or additional securities or other property
(including money paid other than as a regular cash dividend) which is by reason of any such transaction distributed with respect
to the Purchased Shares shall be immediately subject to the Repurchase Right, but only to the extent the Purchased Shares are at
the time covered by such right.  Appropriate adjustments to reflect the distribution of such securities or property shall
be made to the number of Purchased Shares subject to the Repurchase Right hereunder and to the price per share to be paid upon
the exercise of the Repurchase Right in order to reflect the effect of any such transaction upon the Corporation’s capital
structure; provided, however, that the aggregate purchase price to be paid by the Corporation pursuant to the Repurchase Right
shall remain the same.

 

Cancellation of Shares.  If the Corporation
(or its assignees) shall make available, at the time and place and in the amount and form provided in this Amendment, the consideration
for the Purchased Shares to be repurchased in accordance with the provisions of this Agreement, then from and after such time,
the person from whom such shares are to be repurchased shall no longer have any rights as a holder of such shares (other than the
right to receive payment of such consideration in accordance with this Amendment), and such shares shall be deemed purchased in
accordance with the applicable provisions hereof and the Corporation (or its assignees) shall be deemed the owner and holder of
such shares, whether or not the certificates therefor have been delivered as required by this Amendment.

 

Repurchase Obligation .  Upon the termination
of this Agreement, for any reason or for no reason, and regardless of the party who initiated the termination, any Shares which
ApolloMed is not yet obligated to release from Escrow (“Repurchased Shares”) shall be repurchased by the Company at
a price of $0.0001 per Repurchased Share (the “Repurchase Per Share Price”).  ApolloMed shall remit its check
to the Director within 10 business days following such termination in the full amount of the Repurchase Per Share Price multiplied
by the number of Repurchased Shares.  For example, if there were 100,000 Shares remaining in Escrow upon the termination
of this Agreement, ApolloMed would repurchase the 100,000 Shares by remitting its check to the Director in the amount of 100,000
x $0.001 = $100.00.

 

C.    Additional Payments

 

To the extent services described in Section I require out-of-town
trips, such additional travel time may be charged at the rate of $1,200 per day or prorated portion thereof.   This rate
may be revised by action of ApolloMed’s Board of Directors from time to time for payments not yet earned.  Such revision
shall be effective as of the date specified in the resolution and need not be documented by an amendment to this Agreement.

 

D.    Payment

 

Cash fees shall be made quarterly in cash in advance on the
first day of each accounting quarter.  Additional payments shall be made in arrears.  No invoices need be submitted by
the Director for payment of the cash fee.  Invoices for additional payments under subparagraph C of Section IV, above, shall
be submitted by the Director. Such invoices must be approved by ApolloMed’s Chief Executive Officer as to form and completeness.

 

    	4

    	 

    

 

E.    Expenses

 

ApolloMed will reimburse the Director for reasonable expenses
approved in advance, such approval not to be unreasonably withheld.  Invoices for expenses, with receipts attached, shall
be submitted. Such invoices must be approved by ApolloMed’s Chief Executive Officer as to form and completeness.

 

V.      Indemnification and Insurance

 

ApolloMed will execute an indemnification agreement in favor
of the Director substantially in the form of the agreement attached hereto as Exhibit B (the “Indemnification Agreement”). 
In addition, so long as ApolloMed’s indemnification obligations exist under the Indemnification Agreement, ApolloMed shall
provide the Director with directors and officers liability insurance coverage in the amounts specified in the Indemnification Agreement.

 

VI.      Term of Agreement

 

This Agreement shall be in effect from the date hereof through
the last date of the Director’s current term as a member of ApolloMed’s Board of Directors.  This Agreement shall
be automatically renewed on the date of the Director’s reelection as a member of ApolloMed’s Board of Director’s
for the period of such new term unless the Board of Directors determines not to renew this Agreement.   Any amendment
to this Agreement must be approved by a written action of ApolloMed’s Board of Directors.  Amendments to Section IV
Compensation hereof do not require the Director’s consent to be effective.

 

VII.      Termination

 

This Agreement shall automatically terminate upon the death
of the Director or upon his resignation or removal from, or failure to win election or reelection to, the ApolloMed Board of Directors.

 

In the event of any termination of this Agreement, the Director
agrees to return or destroy any materials transferred to the Director under this Agreement except as may be necessary to fulfill
any outstanding obligations hereunder.  The Director agrees that ApolloMed has the right of injunctive relief to enforce this
provision.

 

ApolloMed’s and the Director’s continuing obligations
hereunder in the event of such termination shall be subject to the terms of Section XIV hereof.

 

VIII.      Limitation of Liability

 

Under no circumstances shall ApolloMed be liable to the Director
for any consequential damages claimed by any other party as a result of representations made by the Director with respect to ApolloMed
which are materially different from any to those made in writing by ApolloMed.

 

Furthermore, except for the maintenance of confidentiality,
neither party shall be liable to the other for delay in any performance, or for failure to render any performance under this Agreement
when such delay or failure is caused by Government regulations (whether or not valid), fire, strike, differences with workmen,
illness of employees, flood, accident, or any other cause or causes beyond reasonable control of such delinquent party.

 

    	5

    	 

    

 

IX.      Confidentiality

 

The Director agrees to sign and abide by ApolloMed’s Director
Proprietary Information and Inventions Agreement, a copy of which is attached hereto as Exhibit A.

 

X.      Resolution of Dispute

 

Any dispute regarding the agreement (including without limitation
its validity, interpretation, performance, enforcement, termination and damages) shall be determined in accordance with the laws
of the State of California, the United States of America.  Any action under this paragraph shall not preclude any party hereto
from seeking injunctive or other legal relief to which each party may be entitled.

 

XI.      Sole Agreement

 

This Agreement (including agreements executed in substantially
in the form of the exhibits attached hereto) supersedes all prior or contemporaneous written or oral understandings or agreements,
and may not be added to, modified, or waived, in whole or in part, except by a writing signed by the party against whom such addition,
modification or waiver is sought to be asserted.

 

XII.      Assignment

 

This Agreement and all of the provisions hereof shall be binding
upon and insure to the benefit of the parties hereto and their respective successors and permitted assigns and, except as otherwise
expressly provided herein, neither this Agreement, nor any of the rights, interests or obligations hereunder shall be assigned
by either of the parties hereto without the prior written consent of the other party.

 

XIII.      Notices

 

Any and all notices, requests and other communications required
or permitted hereunder shall be in writing, registered mail or by facsimile, to each of the parties at the addresses set forth
above or the numbers set forth below:

 

	The Director:	Gary Augusta
	 	 
	ApolloMed:	700 N. Brand Blvd, Suite 450
	 	Glendale, CA  91203
	 	Tel: 818-396-8050
	 	Fax: 818-844-3888

 

Any such notice shall be deemed given when received and notice
given by registered mail shall be considered to have been given on the tenth (10th) day after having been sent in the manner provided
for above.

 

XIV.      Survival of Obligations

 

Notwithstanding the expiration of termination of this Agreement,
neither party hereto shall be released hereunder from any liability or obligation to the other which has already accrued as of
the time of such expiration or termination (including, without limitation, ApolloMed’s obligation to make any fees and expense
payments required pursuant to Section IV and/or ApolloMed’s indemnification and insurance obligations set forth in Section
V hereof) or which thereafter might accrue in respect of any act or omission of such party prior to such expiration or termination.

 

    	6

    	 

    

 

XV.      Attorneys’ Fees

 

If any legal action or other proceeding is brought for the enforcement
of this Agreement, or because of a dispute, breach or default in connection with any of the provisions hereof, the successful or
prevailing party (including a party successful or prevailing in defense) shall be entitled to recover its actual attorneys’
fees and other costs incurred in that action or proceeding, in addition to any other relief to which it may be entitled.

 

XV.      Severability

 

Any provision of this Agreement which is determined to be invalid
or unenforceable shall not affect the remainder of this Agreement, which shall remain in effect as though the invalid or unenforceable
provision had not been included herein, unless the removal of the invalid or unenforceable provision would substantially defeat
the intent, purpose or spirit of this Agreement.

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement
to be executed as of the date first written above.

 

	Director:	 	Apollo Medical Holdings, Inc.
	 	 	 
	Signature:  /s/ GARY AUGUSTA	 	Signature: /s/ WARREN HOSSEINION
	 	 	 
	Print Name:	Gary Augusta	 	Print Name: Warren Hosseinion,M.D.
	 	 	 
	 	 	Title: CEO

 

    	7

    	 

    

 

EXHIBIT PROPRIETARY INFORMATION AGREEMENT

 

THIS BOARD OF DIRECTORS PROPRIETARY INFORMATION AGREEMENT
(“Agreement”) is made and entered into this 22nd day of March, 2012 by and between APOLLO MEDICAL HOLDINGS,
INC., a Delaware corporation (“ApolloMed”), and Gary Augusta (the “Director”).

 

RECITALS

 

WHEREAS, the Director has been elected to serve on the Board
of Directors of ApolloMed;

 

WHEREAS, the parties desire to assure the confidential status
of the information which may be disclosed by ApolloMed to the Director in connection with the Director serving on ApolloMed’s
Board of Directors;

 

NOW THEREFORE, in reliance upon and in consideration
of the following undertaking, the parties agree as follows:

 

AGREEMENT

 

1.      
Subject to the limitations set forth in Paragraph 2, all information disclosed by ApolloMed to the Director shall be deemed to
be "Proprietary Information".  In particular, Proprietary Information shall be deemed to include any information,
process, technique, algorithm, program, design, drawing, formula or test data relating to any research project, work in process,
future development, engineering, manufacturing, marketing, servicing, financing or personnel matter relating to ApolloMed, its
present or future products, sales, suppliers, customers, employees, investors, or business, whether or oral, written, graphic or
electronic form.

 

2.      
The term "Proprietary Information" shall not be deemed to include the following information: (i) information which is
now, or hereafter becomes, through no breach of this Agreement on the part of the Director, generally known or available to the
public; (ii) is known by the Director at the time of receiving such information; (iii) is hereafter furnished to the Director by
a third party, as a matter of right and without restriction on disclosure; or (iv) is the subject of a written permission to disclose
provided by ApolloMed.

 

3.      
The Director shall maintain in trust and confidence and not disclose to any third party or use for any unauthorized purpose any
Proprietary Information received from ApolloMed.  The Director may use such Proprietary Information only to the extent required
to accomplish the purposes of his position as a Director of ApolloMed.  The Director shall not use Proprietary Information
for any purpose or in any manner which would constitute a violation of any laws or regulations, including without limitation the
export control laws of the United States.  No other rights of licenses to trademarks, inventions, copyrights, or patents are
implied or granted under this Agreement.

 

4.      
Proprietary Information supplied shall not be reproduced in any form except as required to accomplish the intent of this Agreement.

 

5.      
The Director represents and warrants that he shall protect the Proprietary Information received with at least the same degree of
care used to protect his own Proprietary Information from unauthorized use or disclosure.

 

6.      
All Proprietary Information (including all copies thereof) shall remain in the property of ApolloMed, and shall be returned to
ApolloMed (or destroyed) after the Director's need for it has expired, or upon request of ApolloMed, and in any event, upon the
termination of that certain Board of Directors Agreement, of even date herewith, between ApolloMed and the Director (the “Director
Agreement”).

 

    	8

    	 

    

 

7.      
Notwithstanding any other provision of this Agreement, disclosure of Proprietary Information shall not be precluded if such disclosure:

 

(a)   is in response to a valid order of a court or
other governmental body of the United States or any political subdivision thereof; provided, however, that the Director shall first
have given ApolloMed notice of the Director’s receipt of such order and ApolloMed shall have had an opportunity to obtain
a protective order requiring that the Proprietary Information so disclosed be used only for the purpose for which the order was
issued;

 

(b)   is otherwise required by law; or

 

(c)   is otherwise necessary to establish rights or
enforce obligations under this Agreement, but only to the extent that any such disclosure is necessary.

 

8.      
Subject to the terms of this Paragraph, this Agreement shall continue in full force and effect during the term of the Director
Agreement. This Agreement may be terminated at any time upon thirty (30) days written notice to the other party.  The termination
of this Agreement shall not relieve the Director of the obligations imposed by Paragraphs 3, 4, 5 and 11 of this Agreement with
respect to Proprietary information disclosed prior to the effective date of such termination and the provisions of these Paragraphs
shall survive the termination of this Agreement for a period of eighteen (18) months from the date of such termination.

 

9.     This Agreement
shall be governed by the laws of the State of California as those laws are applied to contracts entered into and to be performed
entirely in California by California residents.

 

10.      This
Agreement contains the final, complete and exclusive agreement of the parties relative to the subject matter hereof and may not
be changed, modified, amended or supplemented except by a written instrument signed by both parties.

 

11.      Each
party hereby acknowledges and agrees that in the event of any breach of this Agreement by the Director, including, without limitation,
an actual or threatened disclosure of Proprietary Information without the prior express written consent of ApolloMed, ApolloMed
will suffer an irreparable injury, such that no remedy at law will afford it adequate protection against, or appropriate compensation
for, such injury.  Accordingly, each party hereby agrees that ApolloMed shall be entitled to specific performance of the Director's
obligations under this Agreement, as well as such further injunctive relief as may be granted by a court of competent jurisdiction.

 

	Director:	 	Apollo Medical Holdings, Inc.
	 	 	 
	Signature:  /s/ GARY AUGUSTA	 	Signature: /s/ WARREN HOSSEINION
	 	 	 
	Print Name:	Gary Augusta	 	Print Name:Warren Hosseinion,M.D.
	 	 	 
	 	 	Title: CEO

 

    	9

    	 

    

 

EXHIBIT B

 

INDEMNIFICATION
AGREEMENT

 

INDEMNIFICATION AGREEMENT (this “Agreement”)
dated as of March 22, 2012, by and among APOLLO MEDICAL HOLDINGS, INC., a Delaware corporation (the “Company”) and
the indemnitees listed on the signature pages hereto (individually, as “Indemnitee” and, collectively, the “Indemnitees”).

 

RECITALS

 

A.        The
Company and Indemnitees recognize the continued difficulty in obtaining liability insurance for its directors, officers, employees,
stockholders, controlling persons, agents and fiduciaries, the significant increases in the cost of such insurance and the general
reductions in the coverage of such insurance.

 

B.         The
Company and Indemnitees further recognize the substantial increase in corporate litigation in general, which subjects directors,
officers, employees, controlling persons, stockholders, agents and fiduciaries to expensive litigation risks at the same time as
the availability and coverage of liability insurance has been severely limited.

 

C.         The
Indemnitees do not regard the current protection available as adequate under the present circumstances, and Indemnitees and other
directors, officers, employees, stockholders, controlling persons, agents and fiduciaries of the Company may not be willing to
serve in such capacities without additional protection.

 

D.         The
Company (i) desires to attract and retain highly qualified individuals and entities, such as Indemnitees, to serve the Company
and, in part, in order to induce each Indemnitee to be involved with the Company and (ii) wishes to provide for the indemnification
and advancing of expenses to each Indemnitee to the maximum extent permitted by law.

 

E.          In
view of the considerations set forth above, the Company desires that each Indemnitee be indemnified by the Company as set forth
herein.

 

NOW, THEREFORE, the Company and each Indemnitee
hereby agree as follows:

 

    	10

    	 

    

 

1.       Indemnification

 

a.      Indemnification
of Expenses. The Company shall indemnify and hold harmless each Indemnitee (including its respective directors, officers,
partners, former partners, members, former members, employees, agents and spouse, as applicable) and each person who controls
any of them or who may be liable within the meaning of Section 15 of the Securities Act of 1933, as amended (the “Securities
Act”), or Section 20 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to the fullest
extent permitted by law if such Indemnitee was or is or becomes a party to or witness or other participant in, or is threatened
to be made a party to or witness or other participant in, any threatened, pending or completed action, suit, proceeding or alternative
dispute resolution mechanism, or any hearing, inquiry or investigation that such Indemnitee believes might lead to the institution
of any such action, suit, proceeding or alternative dispute resolution mechanism, whether civil, criminal, administrative, investigative
or other (hereinafter a “Claim”) by reason of (or arising in part or in whole out of) any event or occurrence related
to the fact that Indemnitee is or was or may be deemed a director, officer, stockholder, employee, controlling person, agent or
fiduciary of the Company, or any subsidiary of the Company, or is or was or may be deemed to be serving at the request of the
Company as a director, officer, stockholder, employee, controlling person, agent or fiduciary of another corporation, partnership,
limited liability company, joint venture, trust or other enterprise, or by reason of any action or inaction on the part of such
Indemnitee while serving in such capacity including, without limitation, any and all losses, claims, damages, expenses and liabilities,
joint or several (including any investigation, legal and other expenses incurred in connection with, and any amount paid in settlement
of, any action, suit, proceeding or any claim asserted) under the Securities Act, the Exchange Act or other federal or state statutory
law or regulation, at common law or otherwise or which relate directly or indirectly to the registration, purchase, sale or ownership
of any securities of the Company or to any fiduciary obligation owed with respect thereto or as a direct or indirect result of
any Claim made by any stockholder of the Company against an Indemnitee and arising out of or related to any round of financing
of the Company (including but not limited to Claims regarding non-participation, or non-pro rata participation, in such round
by such stockholder), or made by a third party against an Indemnitee based on any misstatement or omission of a material fact
by the Company in violation of any duty of disclosure imposed on the Company by federal or state securities or common laws (hereinafter
an “Indemnification Event”) against any and all expenses (including attorneys’ fees and all other costs, expenses
and obligations incurred in connection with investigating, defending a witness in or participating in (including on appeal), or
preparing to defend, be a witness in or participate in, any such action, suit, proceeding, alternative dispute resolution mechanism,
hearing, inquiry or investigation), judgments, fines, penalties and amounts paid in settlement (if, and only if, such settlement
is approved in advance by the Company, which approval shall not be unreasonably withheld) of such Claim and any federal, state,
local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement
(collectively, hereinafter “Expenses”), including all interest, assessments and other charges paid or payable in connection
with or in respect of such Expenses. Such payment of Expenses shall be made by the Company as soon as practicable but in any event
no later than ten (10) days after written demand by the Indemnitee therefor is presented to the Company.

 

b.      Reviewing
Party. Notwithstanding the foregoing, (i) the obligations of the Company under Section 1(a) shall be subject to the condition
that the Reviewing Party (as described in Section 10(e) hereof) shall not have determined (in a written opinion, in any case in
which the Independent Legal Counsel referred to in Section 1(e) hereof is involved) that Indemnitee would not be permitted to
be indemnified under applicable law, and (ii) each Indemnitee acknowledges and agrees that the obligation of the Company to make
an advance payment of Expenses to Indemnitee pursuant to Section 2(a) (an “Expense Advance”) shall be subject to the
condition that, if, when and to the extent that the Reviewing Party determines that Indemnitee would not be permitted to be so
indemnified under applicable law, the Company shall be entitled to be reimbursed by Indemnitee (who hereby agrees to reimburse
the Company) for all such amounts theretofore paid; provided, however, that if Indemnitee has commenced or thereafter commences
legal proceedings in a court of competent jurisdiction to secure a determination that Indemnitee should be indemnified under applicable
law, any determination made by the Reviewing Party that Indemnitee would not be permitted to be indemnified under applicable law
shall not be binding and Indemnitee shall not be required to reimburse the Company for any Expense Advance until a final judicial
determination is made with respect thereto (as to which all rights of appeal therefrom have been exhausted or lapsed). Indemnitee’s
obligation to reimburse the Company for any Expense Advance shall be unsecured and no interest shall be charged thereon. If there
has not been a Change in Control (as defined in Section 10(c) hereof), the Reviewing Party shall be selected by the Board of Directors,
and if there has been such a Change in Control (other than a Change in Control which has been approved by a majority of the Company’s
Board of Directors who were directors immediately prior to such Change in Control), the Reviewing Party shall be the Independent
Legal Counsel referred to in Section 1(e) hereof. If there has been no determination by the Reviewing Party or if the Reviewing
Party determines that Indemnitee substantively would not be permitted to be indemnified in whole or in part under applicable law,
Indemnitee shall have the right to commence litigation seeking an initial determination by the court or challenging any such determination
by the Reviewing Party or any aspect thereof, including the legal or factual bases therefor, and the Company hereby consents to
service of process and to appear in any such proceeding. Any determination by the Reviewing Party otherwise shall be conclusive
and binding on the Company and Indemnitee.

 

    	11

    	 

    

 

c.      Contribution.
If the indemnification provided for in Section 1(a) above for any reason is held by a court of competent jurisdiction to be unavailable
to an Indemnitee in respect of any losses, claims, damages, expenses or liabilities referred to therein, then the Company, in
lieu of indemnifying such Indemnitee thereunder, shall contribute to the amount paid or payable by such Indemnitee as a result
of such losses, claims, damages, expenses or liabilities (i) in such proportion as is appropriate to reflect the relative benefits
received by the Company and the Indemnitee, or (ii) if the allocation provided by clause (i) above is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the
relative fault of the Company and the Indemnitee in connection with the action or inaction which resulted in such losses, claims,
damages, expenses or liabilities, as well as any other relevant equitable considerations. In connection with the registration
of the Company’s securities, the relative benefits received by the Company and the Indemnitee shall be deemed to be in the
same respective proportions that the net proceeds from the offering (before deducting expenses) received by the Company and the
Indemnitee, in each case as set forth in the table on the cover page of the applicable prospectus, bear to the aggregate public
offering price of the securities so offered. The relative fault of the Company and the Indemnitee shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission
to state a material fact relates to information supplied by the Company or the Indemnitee and the parties’ relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission.

 

The Company and the Indemnitee agree that
it would not be just and equitable if contribution pursuant to this Section 1(c) were determined by pro rata or per capita allocation
or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately
preceding paragraph. In connection with the registration of the Company’s securities, in no event shall Indemnitee be required
to contribute any amount under this Section 1(c) in excess of the lesser of (i) that proportion of the total of such losses, claims,
damages or liabilities indemnified against equal to the proportion of the total securities sold under such registration statement
which is being sold by such Indemnitee or (ii) the proceeds received by such Indemnitee from its sale of securities under such
registration statement. No person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) shall be entitled to contribution from any person who was not found guilty of such fraudulent misrepresentation.

 

d.      Survival
Regardless of Investigation. The indemnification and contribution provided for in this Section 1 will remain in full force
and effect regardless of any investigation made by or on behalf of the Indemnitee or any officer, director, employee, agent or
controlling person of the Indemnitee.

 

e.      Change
in Control. The Company agrees that if there is a Change in Control of the Company (other than a Change in Control which has
been approved by a majority of the Company’s Board of Directors who were directors immediately prior to such Change in Control)
then, with respect to all matters thereafter arising concerning the rights of Indemnitee to payments of Expenses under this Agreement
or any other agreement or under the Company’s Certificate of Incorporation, as amended (the “Certificate”),
or Bylaws as now or hereafter in effect, Independent Legal Counsel (as defined in Section 10(d) hereof) shall be selected by the
Indemnitee and approved by the Company (which approval shall not be unreasonably withheld). Such counsel, among other things,
shall render its written opinion to the Company and Indemnitee as to whether and to what extent Indemnitee would be permitted
to be indemnified under applicable law. The Company agrees to abide by such opinion and to pay the reasonable fees of the Independent
Legal Counsel referred to above and to fully indemnify such counsel against any and all expenses (including attorneys’ fees),
claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

 

f.       Mandatory
Payment of Expenses. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee has been successful
on the merits or otherwise, including, without limitation, the dismissal of an action without prejudice, in the defense of any
action, suit, proceeding, inquiry or investigation referred to in Section 1(a) hereof or in the defense of any claim, issue or
matter therein, each Indemnitee shall be indemnified against all Expenses incurred by such Indemnitee in connection herewith.

 

    	12

    	 

    

 

2.       Expenses;
Indemnification Procedure.

 

a.      Advancement
of Expenses. The Company shall advance all Expenses incurred by Indemnitee. The advances to be made hereunder shall be paid
by the Company to Indemnitee as soon as practicable but in any event no later than fifteen (15) days after written demand by such
Indemnitee therefor to the Company.

 

b.      Notice/Cooperation
by Indemnitee. Indemnitee shall give the Company notice as soon as practicable of any Claim made against Indemnitee for which
indemnification will or could be sought under this Agreement. Notice to the Company shall be directed to the Chief Executive Officer
of the Company at the address shown on the signature page of this Agreement (or such other address as the Company shall designate
in writing to Indemnitee).

 

c.      No
Presumptions; Burden of Proof. For purposes of this Agreement, the termination of any Claim by judgment, order, settlement
(whether with or without court approval) or conviction, or upon a plea of nolo contendere, or its equivalent, shall not create
a presumption that Indemnitee did not meet any particular standard of conduct or have any particular belief or that a court has
determined that indemnification is not permitted by applicable law. In addition, neither the failure of the Reviewing Party to
have made a determination as to whether Indemnitee has met any particular standard of conduct or had any particular belief, nor
an actual determination by the Reviewing Party that Indemnitee has not met such standard of conduct or did not have such belief,
prior to the commencement of legal proceedings by Indemnitee to secure a judicial determination that Indemnitee should be indemnified
under applicable law, shall be a defense to Indemnitee’s claim or create a presumption that Indemnitee has not met any particular
standard of conduct or did not have any particular belief. In connection with any determination by the Reviewing Party or otherwise
as to whether Indemnitee is entitled to be indemnified hereunder, the burden of proof shall be on the Company to establish that
Indemnitee is not so entitled.

 

d.      Notice
to Insurers. If, at the time of the receipt by the Company of a notice of a Claim pursuant to Section 2(b) hereof, the Company
has liability insurance in effect which may cover such Claim, the Company shall give prompt written notice of the commencement
of such Claim to the insurers in accordance with the procedures set forth in each of the policies. The Company shall thereafter
take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result
of such action, suit, proceeding, inquiry or investigation in accordance with the terms of such policies.

 

e.      Selection
of Counsel. In the event the Company shall be obligated hereunder to pay the Expenses of any Claim, the Company shall be entitled
to assume the defense of such Claim, with counsel reasonably approved by the applicable Indemnitee, upon the delivery to such
Indemnitee of written notice of its election to do so. After delivery of such notice, approval of such counsel by the Indemnitee
and the retention of such counsel by the Company, the Company will not be liable to such Indemnitee under this Agreement for any
fees of counsel subsequently incurred by such Indemnitee with respect to the same Claim; provided that, (i) the Indemnitee shall
have the right to employ such Indemnitee’s counsel in any such Claim at the Indemnitee’s expense; (ii) the Indemnitee
shall have the right to employ its own counsel in connection with any such proceeding, at the expense of the Company, if such
counsel serves in a review, observer, advice and counseling capacity and does not otherwise materially control or participate
in the defense of such proceeding; and (iii) if (A) the employment of counsel by the Indemnitee has been previously authorized
by the Company, (B) such Indemnitee shall have reasonably concluded that there is a conflict of interest between the Company and
such Indemnitee in the conduct of any such defense, or (C) the Company shall not continue to retain such counsel to defend such
Claim, then the fees and expenses of the Indemnitee’s counsel shall be at the expense of the Company.

 

    	13

    	 

    

 

3.       Additional
Indemnification Rights; Nonexclusivity.

 

a.       Scope.
The Company hereby agrees to indemnify Indemnitee to the fullest extent permitted by law, even if such indemnification is not
specifically authorized by the other provisions of this Agreement or any other agreement, the Certificate, the Company’s
Bylaws or by statute. In the event of any change after the date of this Agreement in any applicable law, statute or rule which
expands the right of a Delaware corporation to indemnify a member of its Board of Directors or an officer, stockholder, employee,
controlling person, agent or fiduciary, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the
greater benefits afforded by such change. In the event of any change in any applicable law, statute or rule which narrows the
right of a Delaware corporation to indemnify a member of its Board of Directors or an officer, employee, agent or fiduciary, such
change, to the extent not otherwise required by such law, statute or rule to be applied to this Agreement, shall have no effect
on this Agreement or the parties’ rights and obligations hereunder except as set forth in Section 8(a) hereof.

 

b.      Nonexclusivity.
Notwithstanding anything in this Agreement, the indemnification provided by this Agreement shall be in addition to any rights
to which Indemnitee may be entitled under the Certificate, the Company’s Bylaws, any agreement, any vote of stockholders
or disinterested directors, the laws of the State of Delaware, or otherwise. Notwithstanding anything in this Agreement, the indemnification
provided under this Agreement shall continue as to each Indemnitee for any action such Indemnitee took or did not take while serving
in an indemnified capacity even though the Indemnitee may have ceased to serve in such capacity and such indemnification shall
inure to the benefit of each Indemnitee from and after Indemnitee’s first day of service as a director with the Company
or affiliation with a director from and after the date such director commences services as a director with the Company.

 

4.       No
Duplication of Payments. The Company shall not be liable under this Agreement to make any payment in connection with any Claim
made against any Indemnitee to the extent such Indemnitee has otherwise actually received payment (under any insurance policy,
Certificate, Bylaws or otherwise) of the amounts otherwise indemnifiable hereunder.

 

5.       Partial
Indemnification. If any Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for
any portion of Expenses incurred in connection with any Claim, but not, however, for all of the total amount thereof, the Company
shall nevertheless indemnify Indemnitee for the portion of such Expenses to which such Indemnitee is entitled.

 

6.       Mutual
Acknowledgement. The Company and each Indemnitee acknowledge that in certain instances, Federal law or applicable public policy
may prohibit the Company from indemnifying its directors, officers, employees, controlling persons, agents or fiduciaries under
this Agreement or otherwise.

 

7.       Liability
Insurance. During any period of time any Indemnitee is entitled to indemnification rights under this Agreement, the Company
shall maintain liability insurance applicable to directors, officers, employees, control persons, agents or fiduciaries, each
Indemnitee shall be covered by such policies in such a manner as to provide Indemnitee the same rights and benefits as are accorded
to the most favorably insured of the Company’s directors, if such Indemnitee is a director, or of the Company’s officers,
if such Indemnitee is not a director of the Company but is an officer; or of the Company’s key employees, controlling persons,
agents or fiduciaries, if such Indemnitee is not an officer or director but is a key employee, agent, control person, or fiduciary.
Said liability insurance shall provide coverage amounts of no less than those specified in Schedule A attached hereto and be held
with an insurance carrier which is the Board of Directors of the Company believes is of financial sound condition.

 

8.       Exceptions.
Any other provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement:

 

a.      Claims
Under Section 16(b). To indemnify any Indemnitee for expenses and the payment of profits arising from the purchase and sale by
such Indemnitee of securities in violation of Section 16(b) of the Exchange Act or any similar successor statute;

 

b.      Unlawful
Indemnification. To indemnify an Indemnitee if a final decision by a court having jurisdiction in the matter shall determine that
such indemnification is not lawful;

 

c.      Fraud.
To indemnify an Indemnitee if a final decision by a court having jurisdiction in the matter shall determine that the Indemnitee
has committed fraud on the Company; or

 

    	14

    	 

    

 

d.      Insurance.
To indemnify any Indemnitee for which payment is actually and fully made to Indemnitee under a valid and collectible insurance
policy.

 

9.       Period
of Limitations. No legal action shall be brought and no cause of action shall be asserted by or in the right of the Company
against any Indemnitee, any Indemnitee’s estate, spouse, heirs, executors or personal or legal representatives after the
expiration of five (5) years from the date of accrual of such cause of action, and any claim or cause of action of the Company
shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such five (5) year period;
provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action, such shorter
period shall govern.

 

10.     Construction
of Certain Phrases.

 

a.      For
purposes of this Agreement, references to the “Company” shall include, in addition to the resulting corporation, any
constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate
existence had continued, would have had power and authority to indemnify its directors, officers, employees, agents or fiduciaries,
so that if Indemnitee is or was or may be deemed a director, officer, employee, agent, control person, or fiduciary of such constituent
corporation, or is or was or may be deemed to be serving at the request of such constituent corporation as a director, officer,
employee, control person, agent or fiduciary of another corporation, partnership, joint venture, employee benefit plan, trust or
other enterprise, each Indemnitee shall stand in the same position under the provisions of this Agreement with respect to the resulting
or surviving corporation as each Indemnitee would have with respect to such constituent corporation if its separate existence had
continued.

 

b.      For
purposes of this Agreement, references to “other enterprises” shall include employee benefit plans; references to “fines”
shall include any excise taxes assessed on any Indemnitee with respect to an employee benefit plan; and references to “serving
at the request of the Company” shall include any service as a director, officer, employee, agent or fiduciary of the Company
which imposes duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect to an employee
benefit plan, its participants or its beneficiaries; and if any Indemnitee acted in good faith and in a manner such Indemnitee
reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan, such Indemnitee shall
be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

 

c.      For
purposes of this Agreement a “Change in Control” shall be deemed to have occurred if (i) any “person” (as
such term is used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act), other than a trustee or other fiduciary holding securities
under an employee benefit plan of the Company or a corporation owned directly or indirectly by the stockholders of the Company
in substantially the same proportions as their ownership of stock of the Company, (A) who is or becomes the beneficial owner, directly
or indirectly, of securities of the Company representing 20% or more of the combined voting power of the Company’s then outstanding
Voting Securities, increases his beneficial ownership of such securities by 5% or more over the percentage so owned by such person,
or (B) becomes the “beneficial owner” (as defined in Rule 13d-3 under said Exchange Act), directly or indirectly, of
securities of the Company representing more than 30% of the total voting power represented by the Company’s then outstanding
Voting Securities, (ii) during any period of two consecutive years, individuals who at the beginning of such period constitute
the Board of Directors of the Company and any new director whose election by the Board of Directors or nomination for election
by the Company’s stockholders was approved by a vote of at least two-thirds (2/3) of the directors then still in office who
either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease
for any reason to constitute a majority thereof, or (iii) the stockholders of the Company approve a merger or consolidation of
the Company with any other corporation other than a merger or consolidation which would result in the Voting Securities of the
Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into
Voting Securities of the surviving entity) at least two-thirds (2/3) of the total voting power represented by the Voting Securities
of the Company or such surviving entity outstanding immediately after such merger or consolidation, or the stockholders of the
Company approve a plan of complete liquidation of the Company or an agreement for the sale or disposition by the Company of (in
one transaction or a series of transactions) all or substantially all of the Company’s assets.

 

    	15

    	 

    

 

d.      For
purposes of this Agreement, “Independent Legal Counsel” shall mean an attorney or firm of attorneys, selected in accordance
with the provisions of Section 1(e) hereof, who shall not have otherwise performed services for the Company or any Indemnitee within
the last three (3) years (other than with respect to matters concerning the right of any Indemnitee under this Agreement, or of
other indemnitees under similar indemnity agreements).

 

e.       For
purposes of this Agreement, a “Reviewing Party” shall mean any appropriate person or body consisting of a member or
members of the Company’s Board of Directors or any other person or body appointed by the Board of Directors who is not a
party to the particular Claim for which Indemnitee is seeking indemnification, or Independent Legal Counsel.

 

f.       For
purposes of this Agreement, “Voting Securities” shall mean any securities of the Company that vote generally in the
election of directors.

 

11.         Counterparts.
This Agreement may be executed in one or more counterparts, each of which shall constitute an original.

 

12.         Binding
Effect; Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the
parties hereto and their respective successors, assigns, including any direct or indirect successor by purchase, merger, consolidation
or otherwise to all or substantially all of the business and/or assets of the Company, spouses, heirs, and personal and legal representatives.
The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise)
to all, substantially all, or a substantial part, of the business and/or assets of the Company, by written agreement in form and
substance satisfactory to each Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the
same extent that the Company would be required to perform if no such succession had taken place. This Agreement shall continue
in effect with respect to Claims relating to Indemnifiable Events regardless of whether any Indemnitee continues to serve as a
director, officer, employee, agent, controlling person, or fiduciary of the Company or of any other enterprise, including subsidiaries
of the Company, at the Company’s request.

 

13.         Attorneys’
Fees. In the event that any action is instituted by an Indemnitee under this Agreement or under any liability insurance policies
maintained by the Company to enforce or interpret any of the terms hereof or thereof, any Indemnitee shall be entitled to be paid
all Expenses incurred by such Indemnitee with respect to such action if such Indemnitee is ultimately successful in such action.
In the event of an action instituted by or in the name of the Company under this Agreement to enforce or interpret any of the terms
of this Agreement, the Indemnitee shall be entitled to be paid Expenses incurred by such Indemnitee in defense of such action (including
costs and expenses incurred with respect to Indemnitee counterclaims and cross-claims made in such action), and shall be entitled
to the advancement of Expenses with respect to such action, in each case only to the extent that such Indemnitee is ultimately
successful in such action.

 

14.         Notice.
All notices and other communications required or permitted hereunder shall be in writing, shall be effective when given, and shall
in any event be deemed to be given (a) five (5) days after deposit with the U.S. Postal Service or other applicable postal service,
if delivered by first class mail, postage prepaid, (b) upon delivery, if delivered by hand, (c) one business day after the business
day of deposit with Federal Express or similar overnight courier, freight prepaid, or (d) one day after the business day of delivery
by facsimile transmission, if deliverable by facsimile transmission, with copy by first class mail, postage prepaid, and shall
be addressed if to Indemnitee, at each Indemnitee’s address as set forth beneath the Indemnitee’s signature to this
Agreement and if to the Company at the address of its principal corporate offices (attention: Secretary) or at such other address
as such party may designate by ten (10) days’ advance written notice to the other party hereto.

 

    	16

    	 

    

 

15.         Severability.
The provisions of this Agreement shall be severable in the event that any of the provisions hereof (including any provision within
a single section, paragraph or sentence) are held by a court of competent jurisdiction to be invalid, void or otherwise unenforceable,
and the remaining provisions shall remain enforceable to the fullest extent permitted by law. Furthermore, to the fullest extent
possible, the provisions of this Agreement (including, without limitations, each portion of this Agreement containing any provision
held to be invalid, void or otherwise unenforceable, that is not itself invalid, void or unenforceable) shall be construed so as
to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.

 

16.         Choice
of Law. This Agreement shall be governed by and its provisions construed and enforced in accordance with the laws of the State
of Delaware, as applied to contracts between Delaware residents, entered into and to be performed entirely within the State of
Delaware, without regard to the conflict of laws principles thereof.

 

17.         Subrogation.
In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights
of recovery of Indemnitee who shall execute all documents required and shall do all acts that may be necessary to secure such rights
and to enable the Company effectively to bring suit to enforce such rights.

 

18.         Amendment
and Termination. No amendment, modification, termination or cancellation of this Agreement shall be effective unless it is
in writing signed by the parties to be bound thereby. Notice of same shall be provided to all parties hereto. No waiver of any
of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not
similar) nor shall such waiver constitute a continuing waiver.

 

19.         Corporate
Authority. The Board of Directors of the Company and its stockholders in accordance with Delaware law have approved the terms
of this Agreement.

 

(Remainder of page intentionally left blank)

 

    	17

    	 

    

 

IN WITNESS
WHEREOF, the parties hereto have executed this Indemnification Agreement on and as of the day and year first above written.

 

	 	 	APOLLO MEDICAL HOLDINGS, INC.,
	 	 	a Delaware corporation
	 	 	 
	 	 	By: /s/ WARREN HOSSEINION, M.D.     
	 	 	Warren Hosseinion, M.D. CEO  
	 	 	 
	 	 	“Indemnitees”
	 	 	 
	 	 	/s/ GARY AUGUSTA
	 	 	Gary Augusta

 

    	18

    	 

    

 

Exhibit C

 

ELECTION UNDER SECTION 83(b) OF

THE INTERNAL REVENUE CODE

 

The undersigned hereby makes an election pursuant
to Section 83(b) of the Internal Revenue Code with respect to the property described below and supplies the following information
in accordance with the regulations promulgated thereunder:

 

1. The name, address
and social security number of the undersigned:

 

Name: Gary Augusta

Address:                                                                            

                                                                                                                

Social Security No.                                                                                 

 

2. Description of property
with respect to which the election is being made:

 

    400,000 shares of common stock
of Apollo Medical Holdings, Inc. (the “Company”).

 

3. The date on which
the property was transferred is               .

 

4. The taxable year to
which this election relates is calendar year               .

 

5. Nature of restrictions
to which the property is subject:

 

The shares of stock are subject to the provisions
of a Restricted Stock Agreement between the undersigned and the Company. The shares of stock are subject to forfeiture under the
terms of the Agreement.

 

6. The fair market value
of the property at the time of transfer (determined without regard to any lapse restriction) was $              
per share, for a total of $               .

 

7. The amount paid by
taxpayer for the property was nothing.

 

8. A copy of this statement
has been furnished to the Company.

 

Dated:

 

	 	 	 
	 	 	Taxpayer’s Signature
	 	 	 
	 	 	 
	 	 	Taxpayer’s Spouse’s Signature

 

    	19

    	 

    

 

PROCEDURES FOR MAKING ELECTION

UNDER INTERNAL REVENUE CODE SECTION 83(b)

 

The following procedures must be followed
with respect to the attached form for making an election under Internal Revenue Code section 83(b) in order for the election to
be effective:

 

A.           You
must file one copy of the completed election form with the IRS Service Center where you file your federal income tax returns within
30 days after the Date of Award of your Restricted Stock.

 

B.           At
the same time you file the election form with the IRS, you must also give a copy of the election form to the Secretary of the Company.

 

C.           You
must file another copy of the election form with your federal income tax return (generally, Form 1040) when it is filed for the
taxable year in which the stock is transferred to you. It is suggested that a copy also be attached to your state income tax return.

 

    	20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}]]